The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3 (original) (raw)

• Lopingco, M. C. & Perkins, A. S. Molecular analysis of Evi1, a zinc finger oncogene involved in myeloid leukemia. Cur. Top. Microbiol. Immunol. 211, 211–222 (1996).
  CAS Google Scholar
• Morishita, K. et al. Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300–400 kilobases on chromosome band 3q26. Proc. Natl Acad. Sci. USA 89, 3937–3941 (1992).
  Article ADS CAS Google Scholar
• Mitani, K. et al. Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J. 13, 504–510 (1994).
  Article CAS Google Scholar
• Ogawa, S. et al. Structurally altered Evi-1 protein generated in the 3q21q26 syndrome. Oncogene 13, 183–191 (1996).
  CAS PubMed Google Scholar
• Ogawa, S. et al. Increased Evi-1 expression is frequently observed in blastic crisis of chronic myelocytic leukemia. Leukemia 10, 788–794 (1996).
  CAS PubMed Google Scholar
• Morishita, K. et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54, 831–840 (1988).
  Article CAS Google Scholar
• Tanaka, T. et al. Evi-1 raises AP-1 activity and stimulates c-fos promoter transactivation with dependence on the second zinc finger domain. J. Biol. Chem. 269, 24020–24026 (1994).
  Article CAS Google Scholar
• Bartholomew, C., Kilbey, A., Clark, A. M. & Walker, M. The Evi-1 proto-oncogene encodes a transcriptional repressor activity associated with transformation. Oncogene 14, 569–577 (1997).
  Article CAS Google Scholar
• Kurokawa, M. et al. The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene 11, 833–840 (1995).
  CAS PubMed Google Scholar
• Morishita, K., Parganas, E., Matsugi, T. & Ihle, J. N. Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol. Cell. Biol. 12, 183–189 (1992).
  CAS PubMed PubMed Central Google Scholar
• Kreider, B. L., Orkin, S. H. & Ihle, J. N. Loss of erythropoietin responsiveness in erythroid progenitors due to expression of the Evi-1 myeloid-transforming gene. Proc. Natl Acad. Sci. USA 90, 6454–6458 (1993).
  Article ADS CAS Google Scholar
• Massagué, J. The transforming growth factor-β family. Annu. Rev. Cell Biol. 6, 597–641 (1990).
  Article Google Scholar
• Zhang, Y., Feng, X., We, R. & Derynck, R. Receptor-associated Mad homologues synergize as effectors of the TGF-β response. Nature 383, 168–172 (1996).
  Article ADS CAS Google Scholar
• Wrana, J. L., Attisano, L., Wieser, R., Ventura, F. & Massagué, J. Mechanism of activation of the TGF-β receptor. Nature 370, 341–347 (1994).
  Article ADS CAS Google Scholar
• Macias-Silva, M. et al. MADR2 is a substrate of the TGFβ receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 87, 1215–1224 (1996).
  Article CAS Google Scholar
• Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 371, 257–261 (1994).
  Article ADS CAS Google Scholar
• Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M. & Massagué, J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62, 175–185 (1990).
  Article CAS Google Scholar
• Derynck, R. & Zhang, Y. Intracellular signalling: the mad way to do it. Curr. Biol. 6, 1226–1229 (1996).
  Article CAS Google Scholar
• Massagué, J. TGFβ signaling: receptors, transducers, and Mad proteins. Cell 85, 947–950 (1996).
  Article Google Scholar
• Wrana, J. L. & Attisano, L. MAD-related proteins in TGFβ signaling. Trends Genet. 12, 493–496 (1996).
  Article CAS Google Scholar
• Wu, R.-Y., Zhang, Y., Feng, X.-H. & Derynck, R. Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4. Mol. Cell. Biol. 17, 2521–2528 (1997).
  Article CAS Google Scholar
• Nakao, A. et al. TGF-β receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J. 16, 5353–5362 (1997).
  Article CAS Google Scholar
• Wieser, R., Wrana, J. L. & Massagué, J. GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF-β receptor complex. EMBO J. 14, 2199–2208 (1995).
  Article CAS Google Scholar
• Yingling, J. M. et al. Tumor suppressor Smad4 is a transforming growth factor β-inducible DNA binding protein. Mol. Cell. Biol. 17, 7019–7028 (1997).
  Article CAS Google Scholar
• Tanaka, T. et al. Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Mol. Cell. Biol. 15, 2383–2392 (1995).
  Article CAS Google Scholar
• Lagna, G., Hata, A., Hemmati, B. A. & Massagué, J. Partnership between DPC4 and SMAD proteins in TGF-β signalling pathways. Nature 383, 832–836 (1996).
  Article ADS CAS Google Scholar
• Hata, A. S. L. R., Wotton, D., Lagna, G. & Massagué, J. Mutations increasing autoinhibition inactive tumor suppressors Smad2 and Smad4. Nature 388, 82–87 (1997).
  Article CAS Google Scholar
• Takebe, Y. et al. SRα promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8, 466–472 (1988).
  CAS PubMed PubMed Central Google Scholar
• Kurokawa, M. et al. Aconserved cysteine residue in the runt homology domain of AML1 is required for the DNA binding ability and the transforming activity on fibroblasts. J. Biol. Chem. 271, 16870–16876 (1996).
  Article CAS Google Scholar